Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

May 13, 2009 16:00 ET

Urodynamix Announces Grant of Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 13, 2009) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) announced today that it has issued 2,000,000 stock options to employees of the Company. The stock options are being offered in conformance with TSX Venture Exchange regulations as incentive compensation and have a term of five years and an exercise price of $0.11 per share.

Following the issuance of these options, Urodynamix has outstanding 107,227,893 common shares and 9,213,500 incentive stock options. The company's Stock Option Plan allows the Board to issue the equivalent of up to 10% of the issued and outstanding share capital of the company on a rolling basis and was approved at the company's last Annual General Meeting held on June 9, 2008.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information